A fresh medical report of Nawaz Sharif has been submitted to LHC. Just days before the Pakistan Muslim League-Nawaz (PML-N) supremo was expected to arrive in Pakistan, a new medical report on the former prime minister Nawaz Sharif was sent to the Lahore High Court (LHC).
The PML-N leader was granted permission by the high court to travel abroad for medical treatment in November 2019 after his medical reports indicated that he required immediate attention.
He traveled to the UK and has been residing in London ever since the LHC granted him permission for medical treatment. He had been ordered by the court to regularly submit medical reports.
The four-year self-imposed exile of Shehbaz Sharif’s elder brother will come to an end on October 21 when he returns to Pakistan, the PML-N president announced last month.
Also read: Bring people to welcome Nawaz Sharif and get Honda 125: PMLN
Professor Carlo di Mario of the Royal Brompton Hospital in London stated in the new medical report submitted today by Nawaz’s legal team that he has been caring for “this patient with previous CABG, multiple angioplasties and ablations, throughout his stay in London in the past years.”
The cardiologist’s antianginal therapy was strengthened by the fact that they had first tried medical treatment.
As a fresh medical report of Nawaz Sharif submitted to LHC, Nawaz Sharif’s ongoing anginal symptoms and the COVID-19 epidemic’s travel restrictions, according to Professor Carlo di Mario, a consultant in interventional cardiology, are to blame for the delay in his safe return to Pakistan.
“When his symptoms worsened and a large area of ischaemia was confirmed in a Rubidium PET myocardial perfusion scan, we decided to repeat an angioplasty. This treatment was performed on November 2022 and targeted an occluded left circumflex artery.”
It required rotational atherectomy, intravascular lithotripsy, multiple stents deployed and expanded under IVUS guidance,” the report stated.
It added that the elder Sharif still has some residual anginal symptoms and suggested continuous monitoring.
“…….due to diffuse distal coronary disease in a patient with diabetes and multiple other comorbidities that would require frequent follow-up investigations both in London and Pakistan.”
